Breakout Stocks
SLDB is part of our breakout stocks list, indicating it is showing strong recent technical strength.
SOLID BIOSCIENCES INC (SLDB) Stock Price & Overview
NASDAQ:SLDB • US83422E2046
Current stock price
8.39 USD
+0.37 (+4.61%)
At close:
8.4488 USD
+0.06 (+0.7%)
After Hours:
The current stock price of SLDB is 8.39 USD. Today SLDB is up by 4.61%. In the past month the price increased by 14.77%. In the past year, price increased by 229.02%.
SLDB Key Statistics
52-Week Range2.41 - 8.72
Current SLDB stock price positioned within its 52-week range.
1-Month Range6.4 - 8.686
Current SLDB stock price positioned within its 1-month range.
- Market Cap
- 825.492M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.02
- Dividend Yield
- N/A
SLDB Stock Performance
Today
+4.61%
1 Week
+8.40%
1 Month
+14.77%
3 Months
+53.38%
Longer-term
6 Months +42.69%
1 Year +229.02%
2 Years -5.41%
3 Years +71.93%
5 Years -89.01%
10 Years N/A
SLDB Stock Chart
SLDB Stock Screens
SLDB currently appears in the following ChartMill screener lists.
SLDB Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SLDB. When comparing the yearly performance of all stocks, SLDB is one of the better performing stocks in the market, outperforming 97.47% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
SLDB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SLDB. No worries on liquidiy or solvency for SLDB as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SLDB Earnings
Next Earnings DateMay 13, 2026
Last Earnings DateMar 19, 2026
PeriodQ4 / 2025
EPS Reported-$0.53
Revenue Reported
EPS Surprise -0.15%
Revenue Surprise %
SLDB Forecast & Estimates
20 analysts have analysed SLDB and the average price target is 17.85 USD. This implies a price increase of 112.75% is expected in the next year compared to the current price of 8.39.
Analysts
Analysts87
Price Target17.85 (112.75%)
EPS Next Y16.35%
Revenue Next YearN/A
SLDB Groups
Sector & Classification
SLDB Financial Highlights
Over the last trailing twelve months SLDB reported a non-GAAP Earnings per Share(EPS) of -2.02. The EPS increased by 33.55% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-174.32M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.97% | ||
| ROE | -96.84% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%47%
Sales Q2Q%N/A
EPS 1Y (TTM)33.55%
Revenue 1Y (TTM)N/A
SLDB Ownership
Ownership
Inst Owners71.36%
Shares98.39M
Float85.53M
Ins Owners0.97%
Short Float %11.75%
Short Ratio7.12
SLDB Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 365.196B | ||
| AMGN | AMGEN INC | 15.32 | 188.577B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.567B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 111.931B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.916B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 44.163B | ||
| INSM | INSMED INC | N/A | 32.624B | ||
| NTRA | NATERA INC | N/A | 28.615B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.011B | ||
| BIIB | BIOGEN INC | 10.94 | 25.883B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.318B | ||
| MRNA | MODERNA INC | N/A | 20.099B | ||
| INCY | INCYTE CORP | 12.34 | 19.015B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SLDB
Company Profile
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. The company also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Company Info
IPO: 2018-01-26
SOLID BIOSCIENCES INC
500 Rutherford Avenue, 3rd Floor
Charlestown MASSACHUSETTS 02139 US
CEO: Ilan Ganot
Employees: 121
Phone: 16173374680
SOLID BIOSCIENCES INC / SLDB FAQ
What does SLDB do?
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. The company also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
What is the stock price of SOLID BIOSCIENCES INC today?
The current stock price of SLDB is 8.39 USD. The price increased by 4.61% in the last trading session.
Does SLDB stock pay dividends?
SLDB does not pay a dividend.
What is the ChartMill rating of SOLID BIOSCIENCES INC stock?
SLDB has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is SOLID BIOSCIENCES INC (SLDB) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SLDB.
Can you provide the number of employees for SOLID BIOSCIENCES INC?
SOLID BIOSCIENCES INC (SLDB) currently has 121 employees.
What is SOLID BIOSCIENCES INC worth?
SOLID BIOSCIENCES INC (SLDB) has a market capitalization of 825.49M USD. This makes SLDB a Small Cap stock.